Relief Therapeutics (OTCMKTS:RLFTF) Shares Up 0.6% – Time to Buy?

Relief Therapeutics Holding SA (OTCMKTS:RLFTFGet Free Report) shares rose 0.6% on Thursday . The stock traded as high as $1.82 and last traded at $1.82. Approximately 1,511 shares were traded during trading, a decline of 6% from the average daily volume of 1,601 shares. The stock had previously closed at $1.81.

Relief Therapeutics Stock Up 0.6%

The firm’s 50 day simple moving average is $2.99 and its 200 day simple moving average is $3.25.

About Relief Therapeutics

(Get Free Report)

Relief Therapeutics AG is a clinical?stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.

The company’s lead product candidate, RLF?100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.

Read More

Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.